Phase I Study of Liposomal Vincristine

• Published in: Journal of clinical oncology Vol. 17; no. 2; pp. 697 - 705
• Main Authors: GELMON, K. A, TOLCHER, A, BURGE, C, LOGAN, P, MAYER, L. D, DIAB, A. R, BALLY, M. B, EMBREE, L, HUDON, N, DEDHAR, C, AYERS, D, EISEN, A, MELOSKY, B
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 01.02.1999; Lippincott Williams & Wilkins
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic agents; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - pharmacokinetics; Biological and medical sciences; Chemotherapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Female; Humans; Infusions, Intravenous; Liposomes; Male; Medical sciences; Middle Aged; Neoplasms - drug therapy; Neoplasms - metabolism; Pharmacology. Drug treatments; Vincristine - administration & dosage; Vincristine - adverse effects; Vincristine - pharmacokinetics; Antineoplastic agent; Human; Increasing dose; Alkaloid; Chemotherapy; Phase I trial; Dosage form; Liposome; Malignant tumor; Pharmacokinetics; Vincristine
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/jco.1999.17.2.697

A phase I study of vincristine encapsulated inside 120-nm-diameter distearoylphosphatidylcholine-cholesterol liposomes was performed. The primary objectives were to determine the maximum-tolerated dose (MTD), recommended phase II dose, toxicity, and pharmacokinetics of liposomal vincristine (ONCO-TCS). Twenty-five patients with histologically confirmed malignancies were enrolled and assessable. Vincristine doses were increased from 0.5 mg/m2 to 1.0, 1.5, 2.0, 2.4, and 2.8 mg/m2 with cohorts of three or more patients per dose level. A total of 64 courses of ONCO-TCS were administered intravenously once every 3 weeks. The pharmacokinetics of total vincristine content in plasma were determined using a high-performance liquid chromatography method. Patients were treated with vincristine doses up to 2.8 mg/m2; however, 2.4 mg/m2 was defined as the MTD and 2.0 mg/m2 as the phase II recommended dose. Pain and obstipation were the dose-limiting toxicites. Other toxicities were fever, rigors, fatigue, myalgias, and peripheral neuropathy. Hematologic toxicity was mild. All patients who were treated with doses above 1.5 mg/m2 received in excess of 2.0 mg of vincristine, with doses as high as 6.2 mg. One partial response was seen in a patient with pancreatic cancer. Tumor response not meeting partial response criteria was seen in two other patients. Pharmacokinetic studies revealed significantly elevated concentrations of total vincristine, but parameters varied and were not directly correlated with toxicity or response. The ability to administer elevated doses of vincristine, as well as indications of efficacy, suggests that ONCO-TCS warrants further clinical investigation in a phase II setting.